The aim of this trial is to investigate the efficacy and safety of intravenous neridronic
acid in subjects with Complex Regional Pain Syndrome (CRPS).
The trial consists of an Enrollment Period lasting up to 60 days, Treatment Period A
consisting of 4 infusions (neridronic acid or placebo) over 10 days, and a Follow-up Period 1
until Week 26.
At Week 26, participants not meeting the pre-specified criteria to continue into Treatment
Period B will continue in Follow-up Period 2 until Week 52. Participants meeting the
pre-specified criteria will enter the open-label Treatment Period B with 4 additional
infusions (neridronic acid) over 10 days and follow-up visits until Week 52.